Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Liver Disease Therapeutics Market Size Kitchen Installation Services Market Size Cholera Vaccines Market Size Jojoba Oil Market SizeGlobal Lung Disease Therapeutics Market Size to Exceed USD 113.1 Billion by 2033
According to a research report published by Spherical Insights & Consulting, The Global Liver Disease Therapeutics Market Size is Expected to Grow from USD 81.3 Billion in 2023 to USD 113.1 Billion by 2033, at a CAGR of 3.36% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Lung Disease Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer, and Other Lung Diseases), By Drug Class (Corticosteroids, Bronchodilator Medications, Mucolytics, Antimicrobial Medications, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033
The lung disease therapeutics market is a worldwide business involved in developing, manufacturing, and distributing drugs and treatments for all kinds of lung diseases. These diseases are asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis, pneumonia, and other respiratory conditions. Furthermore, the world lung disease therapeutics market is stimulated by increasing incidence of respiratory ailments such as COPD, asthma, and lung cancer, elevated air pollution, and rising smoking trends. Technology advancements in drug development, biologics, and inhalation therapies also drive market growth. Support from governments, better healthcare infrastructure, and raising awareness of lung health also propel the market. However, the high treatment costs, stringent regulatory approvals, drug side effects, limited accessibility in developing regions, slow drug development, competition from alternative therapies, and low awareness are key restraints for the growth of the market.
The asthma segment accounted for the greatest share in 2023 and is anticipated to grow at a remarkable CAGR over the forecast period.
On the basis of the disease type, the global lung disease therapeutics market is divided into asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and other lung diseases. Among these, the asthma segment accounted for the greatest share in 2023 and is anticipated to grow at a remarkable CAGR over the forecast period. The segmental growth is attributed to its high global prevalence, increasing air pollution, and rising allergic conditions. Advancements in inhalation therapies, growing adoption of biologics, and government initiatives for respiratory health drive market growth. Expanding healthcare access and ongoing R&D ensure a remarkable CAGR over the forecast period.
The corticosteroid segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period.
On the basis of the drug class, the global lung disease therapeutics market is divided into corticosteroids, bronchodilator medications, mucolytics, antimicrobial medications, and others. Among these, the corticosteroid segment accounted for the greatest share in 2023 and is anticipated to grow at a substantial CAGR over the forecast period. The segmental growth is attributed to its widespread use in treating asthma, COPD, and other lung diseases. Its anti-inflammatory benefits, availability in multiple formulations (inhalers, oral, injectable), and increasing adoption of combination therapies drive growth. Ongoing R&D and rising respiratory disease prevalence ensure substantial CAGR expansion over the forecast period.
The hospital pharmacies segment accounted for the greatest share in 2023 and is anticipated to grow at a significant CAGR over the forecast period.
On the basis of the distribution channel, the global lung disease therapeutics market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the greatest share in 2023 and is anticipated to grow at a significant CAGR over the forecast period. The segmental growth is attributed to the rising hospitalization rates for severe respiratory diseases, increased access to specialized medications, and the availability of advanced lung disease treatments. Growing healthcare infrastructure, expanding patient admissions, and the preference for hospital-based care drive significant CAGR growth over the forecast period.
North America is projected to hold the largest share of the global lung disease therapeutics market over the forecast period.
North America is projected to hold the largest share of the global lung disease therapeutics market over the forecast period. This is due to a high prevalence of respiratory diseases, advanced healthcare infrastructure, and strong pharmaceutical industry presence. Favorable reimbursement policies, increasing adoption of biologics, rising air pollution, and government initiatives for lung health further drive market growth, ensuring the region’s largest market share.
Asia Pacific is expected to grow at the fastest CAGR growth of the global lung disease therapeutics market during the forecast period. This is attributed to the rising air pollution, increasing smoking rates, and a growing prevalence of lung diseases. Expanding healthcare infrastructure, government initiatives, and rising investments in pharmaceutical R&D drive market growth. Additionally, improving access to advanced treatments and a large patient population further accelerates regional market expansion.
Company Profiling
Major vendors in the global lung disease therapeutics market are GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F. Hoffman La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA, and others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global lung disease therapeutics market based on the below-mentioned segments:
Global Lung Disease Therapeutics Market, By Disease Type
Global Lung Disease Therapeutics Market, By Drug Class
Global Lung Disease Therapeutics Market, By Distribution Channel
Global Lung Disease Therapeutics Market, By Regional
May 2025 - The Global Sickle Cell Disease Diagnosis Market Size is Expected to Grow from USD 2.70 Billion in 2023 to USD 11.00 Billion by 2033, at a CAGR of 15.08% during the forecast period 2023-2033.
May 2025 - The Global Rare Disease Genetic Testing Market Size is Expected to Grow from USD 1012.90 Million in 2023 to USD 3788.00 Million by 2033, at a CAGR of 14.10% during the forecast period 2023-2033.
May 2025 - The Global Rare Dermatological Disease Treatment Market Size is Expected to Grow from USD 6.78 Billion in 2023 to USD 11.04 Billion by 2033, at a CAGR of 5.00% during the forecast period 2023-2033.
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com
